



PTO/SB/21 (09-04)

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

8

Application Number

10/817,334

Filing Date

April 2, 2004

First Named Inventor

Hammock, Bruce D.

Art Unit

1654

Examiner Name

To Be Assigned

Attorney Docket Number

02307W-131010US

**ENCLOSURES (Check all that apply)**☐

Fee Transmittal Form

☐

Fee Attached

☐

Amendment/Reply

☐

After Final

☐

Affidavits/declaration(s)

☐

Extension of Time Request

☐

Express Abandonment Request

☒

Information Disclosure Statement

☐

Drawing(s)

☐

Licensing-related Papers

☐

Petition

☐Petition to Convert to a  
Provisional Application☐Power of Attorney, Revocation  
Change of Correspondence Address☐

Terminal Disclaimer

☐

Request for Refund

☐

CD, Number of CD(s) \_\_\_\_\_

☐

Landscape Table on CD

☐

After Allowance Communication to TC

☐Appeal Communication to Board  
of Appeals and Interferences☐Appeal Communication to TC  
(Appeal Notice, Brief, Reply Brief)☐

Proprietary Information

☐

Status Letter

☒Other Enclosure(s) (please identify  
below):References (55);  
Return Postcard☐Certified Copy of Priority  
Document(s)☐Reply to Missing Parts/ Incomplete  
Application☐Reply to Missing Parts  
under 37 CFR 1.52 or 1.53

Remarks

The Commissioner is authorized to charge any additional fees to Deposit  
Account 20-1430.**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name

Townsend and Townsend and Crew LLP

Signature

Printed name

Mark H. Hopkins

Date

April 21, 2005

Reg. No.

44,775

**CERTIFICATE OF TRANSMISSION/MAILING**I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an  
envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.


Signature

Typed or printed name

Jose Luna

Date

April 21, 2005



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

PATENT  
Attorney Docket No.: 02307W-  
131010US  
Client Reference No.: UC No. 2003-033-  
2

On April 21, 2005

TOWNSEND and TOWNSEND and CREW LLP

By: 

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Bruce D. Hammock, et al.

Application No.: 10/817,334

Filed: April 2, 2004

For: IMPROVED INHIBITORS FOR  
THE SOLUBLE EPOXIDE  
HYDROLASE

Examiner: Not yet assigned

Art Unit: 1654

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR §1.97 and  
§1.98

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


The references cited on the attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with the Office's waiver, issued in the August 5, 2003 Official Gazette, copies of the cited U.S. patent publications are not enclosed. Copies of all other references are submitted herewith. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references

be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Mark H. Hopkins  
Reg. No. 44,775

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 925-472-5000  
Fax: 925-472-8895  
MH:jvl  
60396272 v1



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/817,334	
			Filing Date	April 2, 2004	
			First Named Inventor	Hammock, Bruce D.	
			Art Unit	1654	
			Examiner Name	Not yet assigned	
Sheet	1	of	5	Attorney Docket Number	02307W-131010US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
	1.	5,445,956 A	08-29-1995	Hammock et al.	
	2.	5,637,113 A	06-10-1997	Tartaglia et al.	
	3.	6,150,415 A	11-21-2000	Hammock et al.	
	4.	6,287,285 B1	09-11-2001	Michal et al.	
	5.	6,290,722 B1	09-18-2001	Wang	
	6.	6,299,604 B1	10-09-2001	Ragheb et al.	
	7.	6,322,847 B1	11-27-2001	Zhong et al.	
	8.	6,335,029 B1	01-01-2002	Kamath et al.	
	9.	6,351,506 B1	02-26-2002	Lewicki	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
								<input type="checkbox"/>
								<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/817,334
				Filing Date	April 2, 2004
				First Named Inventor	Hammock, Bruce D.
				Art Unit	1654
				Examiner Name	Not yet assigned
Sheet	2	of	5	Attorney Docket Number	02307W-131010US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	10.	ARAND, M. et al., "Sequence similarity of mammalian epoxide hydrolases to the bacterial haloalkane dehalogenase and other related proteins" FEBS Lett., 338:251-256 (1994)		
	11.	ARGIRIADI, M.A. et al., "Binding of alkylurea inhibitors to epoxide hydrolase implicates active site tyrosines in substrate activation" J. Biol. Chem., 275:15265-15270 (2000)		
	12.	ARGIRIADI, M.A. et al., "Detoxification of environmental mutagens and carcinogens: structure, mechanism, and evolution of liver epoxide hydrolase" Proc. Natl. Acad. Sci. USA, 96:10637-10642 (1999)		
	13.	BARDIN, C. W. (ed.), <u>Current Therapy In Endocrinology And Metabolism</u> , 6th Edition, Mosby - Year Book, Inc., St. Louis, MO 1997		
	14.	BEETHAM, J. et al., "cDNA cloning and expression of a soluble epoxide hydrolase from human liver" Arch. Biochem. Biophys., 305(1):197-201 (1993)		
	15.	BEETHAM, J. et al., "Gene evolution of epoxide hydrolases and recommended nomenclature" DNA Cell Biol., 14(1):61-71 (1995)		
	16.	CAMPBELL, W.B., "New role for epoxyeicosatrienoic acids as anti-inflammatory mediators" Trends Pharmacol. Sci., 21:125-127 (2000)		
	17.	CAPDEVILA, J.H. et al., "Cytochrome P450 and arachidonic acid bioactivation: molecular and functional properties of the arachidonate monooxygenase" J. Lipid. Res., 41:163-181 (2000)		
	18.	CARROLL, M.A. et al., "A new class of lipid mediators: cytochrome P450 arachidonate metabolites" Thorax, 55:S13-16 (2000)		
	19.	CHIASSON, J. et al., "The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus" Ann. Intern. Med., 121:928-935 (1994)		
	20.	CONIFF, R. et al., "Multicenter, placebo-controlled trial comparing acarbose (BAY g5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus" Am. J. Med., 98:443-451 (1995)		
	21.	CONIFF, R. et al., "Acarbose: a review of US clinical experience" Clin. Ther., 19:16-26 (1997)		
	22.	DEFRONZO, R. et al. (eds.), "Introduction" Diabetes Reviews, 5(4):293 (1997)		
	23.	DUDDA, A. et al., "Lipid oxidation products in ischemic porcine heart tissue" Chem. Phys. Lipids, 82:39-51 (1996)		
	24.	FANG, X., et al., "Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels" Am. J. Physiol. Heart Circ. Physiol. 287:H2412-H2420 (2004)		
	25.	FISLTHALER, B. et al., "Cytochrome P450 2C is an EDHF synthase in coronary arteries" Nature, 401:493-497 (1999)		
	26.	FRETLAND, A.J. et al., "Epoxide hydrolases: biochemistry and molecular biology" Chem. Biol. Interact., 129:41-59 (2000)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/817,334		
		Filing Date	April 2, 2004		
		First Named Inventor	Hammock, Bruce D.		
		Art Unit	1654		
		Examiner Name	Not yet assigned		
Sheet	3	of	5	Attorney Docket Number	02307W-131010US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	27.	FUKUSHIMA, A. et al., "Cardiovascular effects of leukotoxin (9,10-epoxy-12-octadecenoate) and free fatty acids in dogs" Cardiovasc. Res., 22:213-218 (1988)	
	28.	GIBSON, G.G. and SKETT, P., <u>Introduction to Drug Metabolism</u> , Second Ed., Chapman and Hall, New York pp. 199-210 (1994)	
	29.	GRANT, D. et al., "Molecular cloning and expression of murine liver soluble epoxide hydrolase" J. Biol. Chem., 268(23):17628-17633 (1993)	
	30.	HAFFNER, S., "Management of dyslipidemia in adults with diabetes" Diabetes Care, 21:160-178 (1998)	
	31.	HAMMOCK, B.D. et al., "Chapter 3.18: Epoxide Hyrolases" in <u>Comprehensive Toxicology</u> . Oxford: Pergamon Press pp. 283-305 (1977)	
	32.	HONIG and INGRAM, "Chronic Bronchitis, Emphysema, and Airways Obstruction" in <u>Harrison's Principles of Internal Medicine</u> , (Fauci et al., Eds.), 14th Ed., McGraw-Hill, New York, pp. 1451-1460 (1998)	
	33.	ISHIZAKI, T. et al., "Leukotoxin, 9,10-epoxy-12-octadecenoate causes pulmonary vasodilation in rats" Am. J. Physiol., 268:L123-128 (1995)	
	34.	ISHIZAKI, T. et al., "Leukotoxin, 9,10-epoxy-12-octadecenoate causes edematous lung injury via activation of vascular nitric oxide synthase" Am. J. Physiol., 269:L65-70 (1995)	
	35.	ISHIZAKI, T. et al., "Endothelin-1 potentiates leukotoxin-induced edematous lung injury" J. Appl. Physiol., 79:1106-1611 (1995)	
	36.	IWAMOTO, Y. et al., "Effect of combination therapy of troglitazone and sulphonylureas in patients with type 2 diabetes who were poorly controlled by sulphonylurea therapy alone" Diabet. Med., 13:365-370 (1996)	
	37.	KIM, I., et al., "Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility" J. Med. Chem. 47:2110-2122 (2004)	
	38.	KWITEROVICH, P., "State-of-the-art update and review: clinical trials of lipid-lowering agents" Am. J. Cardiol., 82(12A):3U-17U (1998)	
	39.	MAHLER, R. et al., "Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment" J. Clin. Endocrinol. Metab., 84:1165-71 (1999)	
	40.	MCELROY, N.R. et al., "QSAR and classification of murine and human soluble epoxide hydrolase inhibition by urea-like compounds" J. Med. Chem. 46:1066-1080 (2003)	
	41.	MOGHADDAM, M.F. et al., "Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase" Nat. Med., 3:562-567 (1997)	
	42.	MORISSEAU, C., et al., "Potent urea and carbamate inhibitors of soluble epoxide hydrolases" Proc. Natl. Acad. Sci. USA, 96:8849-8854 (1999)	
	43.	MORISSEAU, C., et al., "Inhibition of microsomal epoxide hydrolases by ureas, amides, and amines" Chem. Res. Toxicol. 14:409-415 (2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/817,334		
		Filing Date	April 2, 2004		
		First Named Inventor	Hammock, Bruce D.		
		Art Unit	1654		
		Examiner Name	Not yet assigned		
Sheet	4	of	5	Attorney Docket Number	02307W-131010US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	44.	MORISSEAU, et al., "Structural refinement of inhibitors of urea-based soluble epoxide hydrolases" Biochem. Pharm., 63:1599-1608 (2002)	
	45.	NAKAGAWA, Y., et al., "3-D QSAR analysis of inhibition of murine soluble epoxide hydrolase (MsEH) by benzoylureas, arylureas, and their analogues" Bioorg. Med. Chem. 8:2663-2673 (2000)	
	46.	NEWMAN, J.W. et al., "Evaluation of fish models of soluble epoxide hydrolase inhibition" Environ. Health Perspect., 109:61-66 (2001)	
	47.	NODE, K. et al., "Anti-inflammatory properties of cytochrome P450 epoxigenase-derived eicosanoids" Science, 285:1276-1279 (1999)	
	48.	OESCH, F. et al., "Mammalian epoxide hydrolases: inducible enzymes catalyzing the inactivation of carcinogenic and cytotoxic metabolites derived from aromatic and olefinic compounds" Xenobiotica, 3:305-340 (1973)	
	49.	OLTMAN, C.L. et al., "Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation" Circ Res., 83:932-939 (1998)	
	50.	OZAWA, T. et al., "Existence of leukotoxin 9,10-epoxy-12-octadecenoate in lung lavages from rats breathing pure oxygen and from patients with the adult respiratory distress syndrome" Am. Rev. Respir. Dis., 137:535-540 (1988)	
	51.	REYNOLDS, H.Y., "Interstitial lung diseases" in <u>Harrison's Principles of Internal Medicine</u> , (Fauci et al., Eds.), 14th Ed., McGraw-Hill, New York, pp. 1460-1466 (1998)	
	52.	SAKAI, T. et al., "Leukotoxin, 9,10-epoxy-12-octadecenoate inhibits mitochondrial respiration of isolated perfused rat lung" Am. J. Physiol., 269:L326-331 (1995)	
	53.	SINAL, C.J. et al., "Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation" J. Biol. Chem., 275:40504-40510 (2000)	
	54.	SPEIZER, "Environmental Lung Diseases," <u>Harrison's Principles of Internal Medicine</u> , (Fauci et al., Eds.), 14th Ed., 1998, McGraw-Hill, New York, pp. 1429-1436	
	55.	TURNER, N. et al., "Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: Current status and therapeutics possibilities" Prog. Drug Res., 51:33-94 (1998)	
	56.	UNITED KINGDOM PROSPECTIVE DIABETES STUDY GROUP, "UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes", Diabetes Care, 21: 87-92 (1998)	
	57.	WALTER, E. et al., "Transepithelial transport properties of peptidomimetic thrombin inhibitors in monolayers of a human intestinal cell line (Caco-2) and their correlation to in vivo data" Pharm. Res., 12: 360-365 (1995)	
	58.	WATANABE, K. et al., "Studies on intestinal absorption of sulpiride (2): transepithelial transport of sulpiride across the human intestinal cell line caco-2" Biol. Pharm. Bull., 25:1345-1350 (2002)	
	59.	WATANABE, T., et al., "In vitro metabolism of the mammalian soluble epoxide hydrolase inhibitor, 1-cyclohexyl-3-dodecyl-urea" Drug Metab. Dispos. 31(7):846-853 (2003)	
	60.	WEINTRAUB, N.L. et al., "Epoxide hydrolases regulate epoxyeicosatrienoic acid incorporation into coronary endothelial phospholipids" Am. J. Physiol., 277:H2098-2108 (1992)	
Examiner Signature		Date Considered	

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/817,334
				Filing Date	April 2, 2004
				First Named Inventor	Hammock, Bruce D.
				Art Unit	1654
				Examiner Name	Not yet assigned
Sheet	5	of	5	Attorney Docket Number	02307W-131010US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	61.	YU, Z. et al., "Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids" Circ. Res., 87:992-998 (2000)		
	62.	ZELDIN, D.C., et al., ""Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase" J. Biol. Chem., 268:6402-6407 (1993)		
	63.	ZHAO, X., et al., "Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage" J. Am. Soc. Nephrol. 15:1244-1253 (2004)		
	64.	ZHENG, J. et al., "Leukotoxin-Diol: a putative toxic mediator involved in acute respiratory distress syndrome" Am. J. Respir. Cell Mol. Biol., 25:434-438 (2001)		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.